10-Q Filing

IMMIX BIOPHARMA, INC. CIK: 1873835 Q1 2023

Filing Information

Form Type	10-Q
Accession Number	`0001493152-23-016721`
Period End Date	20230331
Filing Date	20230512
Fiscal Year	2023
Fiscal Period	Q1
XBRL Instance	form10-q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 64 Income Statement 34 Cash Flow Statement 46 Stockholders Equity 20

Balance Sheet 64 line items

Line Item	Tag	Value	Unit	Period
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$11.46M	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$13.44M	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Tax receivable	`IncomeTaxReceivable`	$322.38K	USD	Point-in-time
Tax receivable	`IncomeTaxReceivable`	$255.71K	USD	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.21M	USD	Point-in-time
Common stock par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses and other current assets	`PrepaidExpenseAndOtherAssetsCurrent`	$1.25M	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	200.00M	shares	Point-in-time
Total current assets	`AssetsCurrent`	$14.90M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$13.03M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	14.02M	shares	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$175.13K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$6.72K	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	13.96M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	13.89M	shares	Point-in-time
Equipment, net	`PropertyPlantAndEquipmentNet`	$3.06K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	13.95M	shares	Point-in-time
Equipment, net	`PropertyPlantAndEquipmentNet`	$3.56K	USD	Point-in-time
Treasury stock, shares	`TreasuryStockCommonShares`	72,363.00	shares	Point-in-time
Treasury stock, shares	`TreasuryStockCommonShares`	72,363.00	shares	Point-in-time
Total assets	`Assets`	$13.21M	USD	Point-in-time
Total assets	`Assets`	$14.91M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.27M	USD	Point-in-time
Accounts payable and accrued expenses	`AccountsPayableAndAccruedLiabilitiesCurrent`	$1.47M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.27M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$1.47M	USD	Point-in-time
Funds held for subsidiary private offering	`FundsHeldForSubsidiaryPrivateOfferingNonCurrent`	$475.00K	USD	Point-in-time
Funds held for subsidiary private offering	`FundsHeldForSubsidiaryPrivateOfferingNonCurrent`	-	USD	Point-in-time
Total liabilities	`Liabilities`	$1.47M	USD	Point-in-time
Total liabilities	`Liabilities`	$1.75M	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies	`CommitmentsAndContingencies`	-	USD	Point-in-time
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding	`PreferredStockValue`	-	USD	Point-in-time
Common stock, $0.0001 par value; 200,000,000 shares authorized; 14,021,185 shares issued and 13,948,822 shares outstanding at March 31, 2023 and 13,964,485 shares issued and 13,892,122 shares outstanding at December 31, 2022	`CommonStockValue`	$1.40K	USD	Point-in-time
Common stock, $0.0001 par value; 200,000,000 shares authorized; 14,021,185 shares issued and 13,948,822 shares outstanding at March 31, 2023 and 13,964,485 shares issued and 13,892,122 shares outstanding at December 31, 2022	`CommonStockValue`	$1.40K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$51.16M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$52.25M	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$87.02K	USD	Point-in-time
Accumulated other comprehensive income	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$82.55K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-40.46M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-37.99M	USD	Point-in-time
Treasury stock at cost, 72,363 shares as of March 31, 2023 and December 31, 2022	`TreasuryStockValue`	$99.96K	USD	Point-in-time
Treasury stock at cost, 72,363 shares as of March 31, 2023 and December 31, 2022	`TreasuryStockValue`	$99.96K	USD	Point-in-time
Total Immix Biopharma, Inc. stockholders equity	`StockholdersEquity`	$11.77M	USD	Point-in-time
Total Immix Biopharma, Inc. stockholders equity	`StockholdersEquity`	$13.16M	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$-32.36K	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	-	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.65M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$17.99M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.74M	USD	Point-in-time
Total stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.16M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$14.91M	USD	Point-in-time
Total liabilities and stockholders equity	`LiabilitiesAndStockholdersEquity`	$13.21M	USD	Point-in-time

Income Statement 34 line items

Line Item	Tag	Value	Unit	Period
General and administrative	`GeneralAndAdministrativeExpense`	$1.20M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$700.51K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$629.53K	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpense`	$1.32M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$2.52M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$1.33M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-1.33M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-2.52M	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	$27.89K	USD	1 Quarter
Interest income	`InvestmentIncomeInterest`	-	USD	1 Quarter
Interest expense	`InterestExpense`	$388.00	USD	1 Quarter
Interest expense	`InterestExpense`	-	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	$-388.00	USD	1 Quarter
Total other income (expense), net	`NonoperatingIncomeExpense`	$27.89K	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-1.33M	USD	1 Quarter
Loss before provision for income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-2.49M	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	$1.62K	USD	1 Quarter
Provision for income taxes	`IncomeTaxExpenseBenefit`	$5.17K	USD	1 Quarter
Net loss	`ProfitLoss`	$-2.50M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.33M	USD	1 Quarter
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	-	USD	1 Quarter
Net loss attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-18.37K	USD	1 Quarter
Net loss attributable to Immix Biopharma, Inc. common stockholders	`NetIncomeLoss`	$-1.33M	USD	1 Quarter
Net loss attributable to Immix Biopharma, Inc. common stockholders	`NetIncomeLoss`	$-2.48M	USD	1 Quarter
Foreign currency translation	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-4.47K	USD	1 Quarter
Foreign currency translation	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$15.59K	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-4.47K	USD	1 Quarter
Total other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$15.59K	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-2.50M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-1.32M	USD	1 Quarter
Loss per common share - basic and diluted	`EarningsPerShareBasic`	$-0.18	USD	1 Quarter
Loss per common share - basic and diluted	`EarningsPerShareBasic`	$-0.10	USD	1 Quarter
Weighted average shares outstanding basic and diluted	`WeightedAverageNumberOfSharesOutstandingBasic`	13.90M	shares	1 Quarter
Weighted average shares outstanding basic and diluted	`WeightedAverageNumberOfSharesOutstandingBasic`	13.83M	shares	1 Quarter

Cash Flow Statement 46 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-2.50M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.33M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$329.92K	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$65.07K	USD	1 Quarter
Depreciation	`Depreciation`	$505.00	USD	1 Quarter
Depreciation	`Depreciation`	$620.00	USD	1 Quarter
Tax receivable	`IncreaseDecreaseInIncomeTaxesReceivable`	$35.96K	USD	1 Quarter
Tax receivable	`IncreaseDecreaseInIncomeTaxesReceivable`	$72.19K	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$353.74K	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$43.01K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$190.81K	USD	1 Quarter
Accounts payable and accrued expenses	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$160.93K	USD	1 Quarter
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	$308.00	USD	1 Quarter
Accrued interest	`IncreaseDecreaseInInterestPayableNet`	-	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-1.49M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-2.09M	USD	1 Quarter
Payments of deferred offering costs	`PaymentOfFinancingAndStockIssuanceCosts`	$160.00K	USD	1 Quarter
Payments of deferred offering costs	`PaymentOfFinancingAndStockIssuanceCosts`	-	USD	1 Quarter
Proceeds from sale of common stock, net of offering costs	`ProceedsFromIssuanceOfCommonStock`	$103.92K	USD	1 Quarter
Proceeds from sale of common stock, net of offering costs	`ProceedsFromIssuanceOfCommonStock`	$2.91M	USD	1 Quarter
Proceeds from sale of Nexcella common stock	`ProceedsFromSaleOfNexcellaCommonStock`	$175.00K	USD	1 Quarter
Proceeds from sale of Nexcella common stock	`ProceedsFromSaleOfNexcellaCommonStock`	-	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$118.92K	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$2.91M	USD	1 Quarter
Effect of foreign currency on cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-2.72K	USD	1 Quarter
Effect of foreign currency on cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-562.00	USD	1 Quarter
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.97M	USD	1 Quarter
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.42M	USD	1 Quarter
Cash and cash equivalents beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$19.06M	USD	Point-in-time
Cash and cash equivalents beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$13.44M	USD	Point-in-time
Cash and cash equivalents beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$11.46M	USD	Point-in-time
Cash and cash equivalents beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$17.64M	USD	Point-in-time
Cash and cash equivalents end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$19.06M	USD	Point-in-time
Cash and cash equivalents end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$13.44M	USD	Point-in-time
Cash and cash equivalents end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$11.46M	USD	Point-in-time
Cash and cash equivalents end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$17.64M	USD	Point-in-time
Interest paid	`InterestPaidNet`	$80.00	USD	1 Quarter
Interest paid	`InterestPaidNet`	-	USD	1 Quarter
Income taxes paid	`IncomeTaxesPaidNet`	$1.62K	USD	1 Quarter
Income taxes paid	`IncomeTaxesPaidNet`	$5.17K	USD	1 Quarter
Nexcella shares issued for funds previously received	`NexcellaSharesIssuedForFundsPreviouslyReceived`	-	USD	1 Quarter
Nexcella shares issued for funds previously received	`NexcellaSharesIssuedForFundsPreviouslyReceived`	$475.00K	USD	1 Quarter
Accrual of deferred offering costs	`AccrualOfDeferredOfferingCosts`	-	USD	1 Quarter
Accrual of deferred offering costs	`AccrualOfDeferredOfferingCosts`	$11.00K	USD	1 Quarter
Deferred offering costs charged against proceeds from sale of common stock	`DeferredOfferingCostsChargedAgainstProceedsFromSaleOfCommonStock`	-	USD	1 Quarter
Deferred offering costs charged against proceeds from sale of common stock	`DeferredOfferingCostsChargedAgainstProceedsFromSaleOfCommonStock`	$2.59K	USD	1 Quarter

Stockholders Equity 20 line items

Line Item	Tag	Value	Unit	Period
Beginning balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.65M	USD	Point-in-time
Beginning balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$17.99M	USD	Point-in-time
Beginning balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.74M	USD	Point-in-time
Beginning balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.16M	USD	Point-in-time
Shares issued under ATM facility for cash proceeds, net of offering costs	`StockIssuedDuringPeriodValueUnderAtmFacilityForCashProceedsNetOfOfferingCosts`	$101.32K	USD	1 Quarter
Shares issued under ATM Facility for cash proceeds, net of offering costs, shares	`StockIssuedDuringPeriodSharesUnderAtmFacilityForCashProceedsNetOfOfferingCosts`	50,000.00	shares	1 Quarter
Nexcella shares issued for cash proceeds	`StockIssuedDuringPeriodValueOther`	$650.00K	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$329.92K	USD	1 Quarter
Stock-based compensation	`StockIssuedDuringPeriodValueShareBasedCompensation`	$65.07K	USD	1 Quarter
Non-controlling interests in subsidiary	`NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance`	-	USD	1 Quarter
Net loss	`ProfitLoss`	$-2.50M	USD	1 Quarter
Net loss	`ProfitLoss`	$-1.33M	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax`	$15.59K	USD	1 Quarter
Foreign currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax`	$-4.47K	USD	1 Quarter
Shares issued for cash proceeds, net of offering costs	`StockIssuedDuringPeriodValueNewIssues`	$2.91M	USD	1 Quarter
Shares issued for cash proceeds, net of offering costs, shares	`StockIssuedDuringPeriodSharesNewIssues`	5.00M	shares	Point-in-time
Ending balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$19.65M	USD	Point-in-time
Ending balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$17.99M	USD	Point-in-time
Ending balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$11.74M	USD	Point-in-time
Ending balance, value	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$13.16M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.